Seeking Alpha / - 21 hours ago
VANCOUVER, BC, July 2, 2025 /PRNewswire/ -- MiniTool Software Limited has released a new version of its video conversion tool – MiniTool Video Converter 4.3. This update brings a new video compression feature and optimizes the interface. Upgrade Highlights in MiniTool Video Converter 4.3...
Seeking Alpha / - 21 hours ago
ENGLEWOOD, Colo., July 02, 2025 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ: IOSP) today announced that it will release second quarter 2025 earnings results on Tuesday, August 5, 2025 after market close. Following the release of its results, Patrick S. Williams, President and Chief Executive Officer...
Seeking Alpha / - 21 hours ago
MIAMI BEACH, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- The Herzfeld Caribbean Basin Fund, Inc. (NASDAQ: CUBA) (the “Fund”) today announced that it has changed the name of the Fund to “Herzfeld Credit Income Fund, Inc.” and that effective on or about July 7, the Fund will continue to trade on NASDAQ...
Seeking Alpha / - 21 hours ago
OKOTOKS, Alberta, July 02, 2025 (GLOBE NEWSWIRE) -- (TSX: MTL) Mullen Group Ltd. ("Mullen Group" and/or the "Corporation") intends to release its 2025 Second Quarter earnings results on Thursday, July 24, 2025, at 6:00 a.m. ET, and has scheduled a conference call and webcast as follows:
Seeking Alpha / - 21 hours ago
DELRAY BEACH, Fla., July 2, 2025 /PRNewswire/ -- The probiotics in animal feed market is projected to expand from USD 5.40 billion in 2025 to USD 8.27 billion by 2030, at a CAGR of 8.9% during the forecast period, according to a report published by MarketsandMarkets™. The probiotics in...
Seeking Alpha / - 21 hours ago
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Mercer International Inc. (“Mercer” or the “Company”) (Nasdaq: MERC), a global forest products company with operations in Germany, the U.S., and Canada, announces that it has received an updated ESG Risk Rating of 16.8 from Sustainalytics. This updated s...
Seeking Alpha / - 21 hours ago
SAN FRANCISCO, July 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that...
Seeking Alpha / - 21 hours ago
DUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced that it has granted a...
Seeking Alpha / - 21 hours ago
JV secures $57 million construction loan from JPMorgan Chase JV secures $57 million construction loan from JPMorgan Chase
Seeking Alpha / - 21 hours ago
WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective July 1, 2025, the company granted non...
Seeking Alpha / - 21 hours ago
Conference Call Scheduled for 8:00 a.m. ET on July 31, 2025 Conference Call Scheduled for 8:00 a.m. ET on July 31, 2025
Seeking Alpha / - 21 hours ago
Seeking Alpha / - 21 hours ago
FREEHOLD, NJ, July 02, 2025 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE: UMH; TASE: UMH) closed on the acquisition of two manufactured home communities, located in Conowingo, Maryland, for a total purchase price of $14.625 million. These communities contain 191 developed homesites, of which 79%...
Seeking Alpha / - 21 hours ago
PERRYSBURG, Ohio, July 02, 2025 (GLOBE NEWSWIRE) -- O-I Glass, Inc. (NYSE: OI) has scheduled its second quarter 2025 conference call and webcast for Wednesday, July 30, 2025, at 8 a.m. EDT. The Company’s news release for the second quarter 2025 earnings will be issued after the market closes on Tu...
Seeking Alpha / - 21 hours ago
Proceeds to drive development of ONP-002, the Company’s lead intranasal drug candidate for mild traumatic brain injury Proceeds to drive development of ONP-002, the Company’s lead intranasal drug candidate for mild traumatic brain injury